Dishman Carbogen Amcis Ltd. focuses on the research and development of several in-house technologies to manufacture quaternary ammonium compounds and active pharmaceutical ingredients (API). It was founded in 1983, with its headquarters in Ahmedabad, Gujarat. During the June 2022 quarter, the company reported a total income of Rs 546.28 crore, down 4.72% from the previous quarter that ended in March 2022. On 21 October 2022, Dishman Carbogen Amcis Ltd.’s market capitalisation stood at Rs 1,568 crore.
The company is listed on the Bombay Stock Exchange with the code 540701, and on the National Stock Exchange with the code DCAL.
Dishman Carbogen Amcis Ltd. manufactures and supplies marketable molecules, such as vitamins and chemicals, speciality chemicals, and disinfectants. The company’s segments include quats, speciality chemicals, vitamin D, bulk drugs, and traded goods. Its first facility was established in 1987 in Naroda, near Ahmedabad. The company has a global presence with multiple manufacturing facilities in India, China, and Europe, serving healthcare, biopharmaceutical, pharmaceutical, and general industries.
On 30 June 2022, the company’s shareholding pattern represented a 59.32% promoter stake, which belongs to Adimans Technologies LLP, 5.85% FII stake, 6.64% DII stake, and 28.19% public stake. In the June 2022 quarter, mutual fund holdings decreased from 6.75% to 6.54%, and FII holdings increased from 5.50% to 5.85%. The company’s quarterly net sales for June 2022 were Rs 103.61 crore, up 62.12% from Rs 63.91 crore in June 2021.
Dishman Carbogen Amcis Ltd.’s leadership team comprises Mr Arpit Vyas, Mr Paolo Armanino, Mr Harshil Dalal, Mr Pascal Villemagne, Mr Alan Fischer, Mr Stephan Fritschi, Mr Robert J Eijkman, and Mr Martin Schneider. The auditors are V D Shukla & Co. and Haribhakti & Co. LLP. As of 30 June 2022, the company had a total of 15.68 crore shares outstanding.
On 21 October 2022, the company’s share price closed at Rs 99.90 on BSE. On NSE, it closed at Rs 100.05. The share price touched a 52-week high of Rs 258.40 and a 52-week low of Rs 90.10. By investing in Dishman Carbogen Amcis Ltd.’s share, investors earned a six-month return of -45.82% and a one-year return of -53.15%.
The company’s peers include Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Divis Laboratories Ltd.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: email@example.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.